α-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis

  • K. Hager
  • M. Kenklies
  • J. McAfoose
  • J. Engel
  • G. Münch
Conference paper
Part of the Journal of Neural Transmission. Supplementa book series (NEURALTRANS, volume 72)


Oxidative stress and neuronal energy depletion are characteristic biochemical hallmarks of Alzheimer’s disease (AD). It is therefore conceivable that pro-energetic and antioxidant drags such as α-lipoic acid might delay the onset or slow down the progression of the disease. In a previous study, 600 mg α-lipoic acid was given daily to nine patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of 12 months. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (the mini mental state exam, MMSE and the Alzheimer’s disease assessment score cognitive subscale, ADAScog). In this report, we have extended the analysis to 43 patients over an observation period of up to 48 months. In patients with mild dementia (ADAScog < 15), the disease progressed extremely slowly (ADAScog: +1.2 points/year, MMSE:-0.6 points/year), in patients with moderate dementia at approximately twice the rate. However, the progression appears dramatically lower than data reported for untreated patients or patients on choline-esterase inhibitors in the second year of long-term studies. Despite the fact that this study was not double-blinded, placebo-controlled and randomized, our data suggest that treatment with α-lipoic acid might be a successful ‘neuroprotective’ therapy option for AD. However, a state-of-the-art phase II trial is needed urgently.


Dementia Alzheimer’s disease lipoic acid neuroprotection open clinical trial 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115CrossRefGoogle Scholar
  2. Biewenga GP, Haenen GR, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29: 315–331PubMedGoogle Scholar
  3. Farlow MR, Lilly ML, Group EBS (2005) Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years. BMC Geriatrics 5: 3PubMedCrossRefGoogle Scholar
  4. Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ (1997) A multicenter evaluation of new treatment efficacy instruments for Alzheimer’s disease clinical trials, overview and general results. Alzheimer Dis Assoc Disord 11: S1–S12PubMedCrossRefGoogle Scholar
  5. Frölich L, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittelforschung 45: 443–446PubMedGoogle Scholar
  6. Galasko DR, Gould RL, Abramson IS, Salmon DP (2000) Measuring cognitive change in a cohort of patients with Alzheimer’s disease. Stat Med 19: 1421–1432PubMedCrossRefGoogle Scholar
  7. Götz ME, Kunig G, Riederer P, Youdim MB (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37–122PubMedCrossRefGoogle Scholar
  8. Hager K, Marahrens A, Kenklies M, Riederer P, Münch G (2001) Alphalipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 32: 275–282PubMedCrossRefGoogle Scholar
  9. Han L, Cole M, Bellavance F, McCusker J, Primeau F (2000) Tracking cognitive decline in Alzheimer’s disease using the Mini-Mental State examination: a meta-analysis. Int Psychogeriatr 12: 231–247PubMedCrossRefGoogle Scholar
  10. Haxby JV, Raffaele K, Gillette J, Schapiro MB, Rapoport SI (1992) Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type. J Clin Exp Neuropsychol 14: 575–592PubMedGoogle Scholar
  11. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Munch G (2006) Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacol Ther 113: 154–164PubMedCrossRefGoogle Scholar
  12. Mohs RC (1996) Comprehensive and neuropsychologic evaluations: the Alzheimer’s disease assessment scale. Int Psychogeriatr 8: 195–203PubMedCrossRefGoogle Scholar
  13. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P (1998) Alzheimer’s disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105: 439–461PubMedCrossRefGoogle Scholar
  14. Packer L, Witt EH, Tritschler HJ (1995) alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227–250PubMedCrossRefGoogle Scholar
  15. Perry G, Castellani RJ, Hirai K, Smith MA (1998) Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1: 45–55PubMedGoogle Scholar
  16. Rascovsky K, Salmon DP, et al. (2005) Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 65: 397–403PubMedCrossRefGoogle Scholar
  17. Retz W, Gsell W, Münch G, Rösier M, Riederer P (1998) Free radicals in Alzheimer’s disease. J Neural Transm Suppl 54: 221–236PubMedGoogle Scholar
  18. Rösier M, Retz W, Thome J, Riederer P (1998) Free radicals in Alzheimer’s dementia: currently available therapeutic strategies. J Neural Transm Suppl 54: 211–219Google Scholar
  19. Stern R, Mohs R, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E (1994) A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151: 390–396PubMedGoogle Scholar
  20. Storey E, Slavin MJ, Kinsella GJ (2002) Patterns of cognitive impairment in Alzheimer’s disease: assessment and differential diagnosis. Front Biosci 7: el55–el84CrossRefGoogle Scholar
  21. Van Gool AW, Weinstein HC, Scheltens P, Walstra GJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358: 455–460PubMedCrossRefGoogle Scholar
  22. Winblad B, Engedal K, et al. (2001) A 1-year, randomized, placebocontrolled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495PubMedGoogle Scholar
  23. Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, Münch G (2001) Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 14: 1961–1967PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • K. Hager
    • 1
  • M. Kenklies
    • 1
  • J. McAfoose
    • 3
  • J. Engel
    • 2
  • G. Münch
    • 3
  1. 1.Department of Medical Rehabilitation and GeriatricsHannoverGermany
  2. 2.Zentaris GmbHFrankfurt am MainGermany
  3. 3.Comparative Genomics Centre, Department of Biochemistry and Molecular BiologyJames Cook UniversityTownsvilleAustralia

Personalised recommendations